Vienna—As checkpoint inhibitor therapy is introduced into additional solid tumor types, investigators and clinicians are learning how patients respond to these agents in the longer term.
The Keynote Oncology Clinical Trial series of the anti–programmed death ligand-1 (PD-L1) agent pembrolizumab (Keytruda, Merck) continues to provide such data, and one of the latest reports is a two-year follow-up from KEYNOTE-010, testing the drug in previously treated patients with